MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
New FDA Guidance to Support Ultra-Rare Disease Drug Development
Antisense oligonucleotide (ASO) drug products target a specific sense mRNA to modulate gene expression in living cells and have been used successfully to treat diseases where the pathogenic mutation has been identified. For patients with an...
Looking back at 2021 – MMS Holdings year in review
2021 brought more challenges and opportunities than ever before. From the starts and stops of opening workplaces, schools and economies to managing an overflowing email inbox, it can be challenging to keep up with all the information you need. So, we rounded up...
MMS Strengthens Leadership in the Area of Project Advisory Services
CANTON, Mich. (12/15/2021) – MMS Holdings Inc., an award-winning, data-focused CRO, announced a restructuring of their consulting services with the launch of a Project Advisory Services Unit to meet the needs of many small to mid-sized organizations in immediate,...
MMS Holdings Wins 2021 Scrip Award for Best Contract Research Organization
CANTON, Mich. (12/8/2021) - MMS Holdings, a data-focused CRO, is pleased to announce its selection as Best Contract Research Organization – Specialist Providers in the 2021 Scrip Awards. The Scrip Awards, held annually by London-based Informa Pharma...
FDA Expedited Program Designations to Support Rare Disease Drug Development
One in 10 Americans is affected by rare diseases—more than half of which are children—and approximately 95% of the more than 7,000 rare diseases have no available treatments. To advance the development of rare disease treatments, the Food and Drug Administration...
Former Astellas VP of Biostatistics Joins MMS as Principal Advisor of Biostatistics
CANTON, Mich. (November 18, 2021) – MMS Holdings – a data-focused CRO – announced this week the addition of Kevin Chartier, Ph.D., as Principal Advisor of Biostatistics and Submissions Planning. Chartier will work with the biostatistics team across MMS global...
MMS Holdings is the Winner of The Michigan Top Workplaces 2021 Award
CANTON, Mich. (11/15/2021) – MMS has been named a 2021 award winner of the Michigan Top Workplaces by the Detroit Free Press Top Workplaces. The award is based solely on employee feedback from an anonymous survey measuring 15 culture drivers that are critical to the...
Second Annual Global Champions of Change Competition Winner
MMS has just concluded its second annual Global Champions of Change Competition (G3C), where colleagues from all MMS regions submitted innovative ideas based on our tradition of providing high-quality, efficient services to our clients to help discover and market...
Praxis bioresearch seeks support from MMS for Alzheimers Disease Therapeutics
SACRAMENTO, Calif. (October 28, 2021) - MMS Holdings (MMS) – a data-focused CRO – provided regulatory strategy support to Praxis Bioresearch in the development of a therapeutic for apathy in Alzheimer’s disease. This comes as Praxis was awarded a $2.9 Million...